Categories Earnings, Health Care

Akebia Therapeutics (AKBA) Q4 2019 Earnings Snapshot

— Akebia Therapeutics (NASDAQ: AKBA) reported fourth quarter 2019 loss of $0.79 per share vs. expected loss of $0.47 per share.

— Revenue rose 16% to $69.6 million vs. $93.15 million expected.

Earnings Update by AlphaStreet

— Net product revenue more than quadrupled to $28.9 million from $6.8 million in the fourth quarter of 2018.

— R&D expenses were $80.4 million for the fourth quarter of 2019 compared to $87.1 million for the fourth quarter of 2018.

— Akebia continues to expect to share the data from global Phase 3 studies of its anemia treatment drug Vadadustat in the second quarter of 2020.

— AKBA stock dipped more than 5% in the pre-market trading session.

We’re on Flipboard! Follow us to receive the latest stock market, earnings, and financial news at your fingertips

Most Popular

After mixed Q4, Darden Restaurants stays focused on profitable sales growth

Darden Restaurants, Inc. (NYSE: DRI), which owns popular restaurant brands Olive Garden and LongHorn Steakhouse, has reported stronger-than-expected fourth-quarter results, sending the stock higher soon after the announcement. Contributions from

What to expect when McCormick & Company (MKC) reports Q2 2024 earnings results

Shares of McCormick & Company, Incorporated (NYSE: MKC) stayed green on Friday. The stock has dropped 4% over the past one month. The spices and condiments maker is scheduled to report

CarMax (KMX) Q1 2025 Earnings: Key financials and quarterly highlights

CarMax, Inc. (NYSE: KMX) reported its first quarter 2025 earnings results today. Net sales and operating revenues decreased 7.5% year-over-year to $7.1 billion. Net earnings decreased 33% to $152.4 million,

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top